Skip to main content
. 2019 Mar 26;2019(3):CD008521. doi: 10.1002/14651858.CD008521.pub4

Analysis 1.28.

Analysis 1.28

Comparison 1 RV1 versus placebo, Outcome 28 Adverse events requiring discontinuation (end of follow‐up).